Edgewise Therapeutics
EWTX
39.57
-0.45
-1.12%
Edgewise Therapeutics
US · EWTX
#2209 by market cap
Listed 2021
39.57
-0.45
-1.12%
Live - 5344 symbols - heartbeat 80s ago
· 2026-10-08 08:06
Pre-market
39.99
+1.06%
After-hours
40.26
+1.74%
- Market cap
- 4.30B
- P/E (TTM)i
- -21.39
- P/Bi
- 9.59
- EPSi
- -1.63
- Div yieldi
- 0.00%
- 52W posi
- 74%
Reader sentiment
Are you bullish or bearish on EWTX?
Anonymous reader poll. Unscientific, not investment advice.
✦ Quant Ownership Signal how this is computed
Distributing
- The number of reporting institutions decreased by 3 in the most recent period (2026/Q3).
- Total institutional ownership fell 1.2 percentage points.
Institutional ownership
- Held by institutions
- 111.09% -1.23pp
- Institutions
- 281 -3
- As of
- 2026/Q3 vs. prior period
Ownership vs. money flow
AlignedInstitutions trimmed shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two line up.
Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.
Holder types
Mutual Fund45.42%
VC/PE Fund35.91%
Hedge Fund23.86%
Public Company4.25%
Government Pension Fund0.59%
Sovereign Wealth Fund0.48%
Private Company0.38%
Individual/Insider0.19%
Family Office/Trust0.11%
Top holders as of 2026-06-30
OrbiMed Advisors LLC
14.29% · 15.52M sh
Paradigm Biocapital Advisors LP
9.41% · 10.22M sh
RA Capital Management, L.P.
7.73% · 8.39M sh
BlackRock
6.08% · 6.61M sh
Janus Henderson Group plc
5.59% · 6.08M sh
FMR
5.05% · 5.49M sh
Novo Holdings A/S
4.93% · 5.35M sh
Driehaus Capital Management LLC
4.35% · 4.73M sh
Vanguard Capital Management, LLC
4.06% · 4.41M sh
Perceptive Advisors LLC
4.03% · 4.37M sh
Bar length is relative to the largest holder shown here, not to 100% of the company.
Insiders
50 filings tracked · 35 buys · 15 sells
| Name | Role | Stake |
|---|---|---|
| OrbiMed Advisors LLC | -- | 14.29% |
| Kevin Koch | Chief Executive Officer | 0.05% |
| Behrad Derakhshan | Chief Business Officer | 0.03% |
| Alan Russell | Co-Founder, Chief Scientific Officer & Director | 0.03% |
| Jonathan Fox | Independent Director | 0.02% |
| Badreddin Edris | Co-Founder & Independent Director | 0.02% |
| John Moore | General Counsel | 0.02% |
| Jonathan Root | Independent Director | 0.01% |
| Joanne Donovan | Chief Medical Officer | 0.01% |
| Robert Blaustein | Chief Development Officer | 0.01% |
Insider transactions most recent Form 4 filings
| Date | Name | Role | Type | Shares | Price |
|---|---|---|---|---|---|
| 2026-09-30 | Jonathan Fox | Independent Director | Other Acquisition | +308 | -- |
| 2026-08-12 | Joanne Donovan | Chief Medical Officer | Derivative Exercise and Sale | -9,441 | $43.41–44.52 |
| 2026-08-11 | Kevin Koch | Chief Executive Officer | Derivative Exercise and Sale | -17,971 | $43.64–44.33 |
| 2026-08-11 | Kevin Koch | Chief Executive Officer | Other Derivative Acquisition | +100,000 | -- |
| 2026-08-11 | Kevin Koch | Chief Executive Officer | Other Derivative Acquisition | +200,000 | $43.56 |
| 2026-08-11 | Kevin Koch | Chief Executive Officer | Derivative Exercise and Retained | +21,873 | -- |
| 2026-08-11 | John Moore | General Counsel | Derivative Exercise and Sale | -5,016 | $43.80–44.50 |
| 2026-08-11 | John Moore | General Counsel | Other Derivative Acquisition | +32,500 | -- |
| 2026-08-11 | John Moore | General Counsel | Other Derivative Acquisition | +65,000 | $43.56 |
| 2026-08-11 | John Moore | General Counsel | Derivative Exercise and Retained | +7,483 | -- |
| 2026-08-11 | Joanne Donovan | Chief Medical Officer | Other Derivative Acquisition | +32,500 | -- |
| 2026-08-11 | Joanne Donovan | Chief Medical Officer | Other Derivative Acquisition | +65,000 | $43.56 |
| 2026-08-11 | Joanne Donovan | Chief Medical Officer | Derivative Exercise and Retained | +3,371 | -- |
| 2026-08-11 | Behrad Derakhshan | Chief Business Officer | Derivative Exercise and Sale | -5,100 | $43.70–44.50 |
| 2026-08-11 | Behrad Derakhshan | Chief Business Officer | Other Derivative Acquisition | +50,000 | -- |
| 2026-08-11 | Behrad Derakhshan | Chief Business Officer | Other Derivative Acquisition | +100,000 | $43.56 |
| 2026-08-11 | Behrad Derakhshan | Chief Business Officer | Derivative Exercise and Retained | +8,181 | -- |
| 2026-08-11 | Michael Nofi | Chief Financial Officer | Other Derivative Acquisition | +24,375 | -- |
| 2026-08-11 | Michael Nofi | Chief Financial Officer | Other Derivative Acquisition | +48,750 | $43.56 |
| 2026-08-11 | Alan Russell | Co-Founder, Chief Scientific Officer & Director | Derivative Exercise and Sale | -5,901 | $43.68–44.46 |
Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.
Quote time 2026-10-08 08:06:22 · For reference only, not investment advice and not tailored to your situation.